Groups | p a | ||
---|---|---|---|
Fish oil (n = 18) | Placebo (n = 19) | ||
Age (years) b | 48.6 ± 9.0 | 53.4 ± 7.5 | 0.107 |
Education level (years) b | 7.2 ± 3.9 | 9.1 ± 4.0 | 0.227 |
Menopause % (n) | |||
No | 50.0 (9) | 26.3 (5) | 0.138 |
Yes | 50.0 (9) | 73.7 (14) | |
Histological type % (n) | |||
Ductal carcinoma in situ (DCIS) | 22.2 (4) | 10.5 (2) | 0.756 |
Infiltrating ductal carcinoma (IDC) | 72.2 (13) | 78.9 (15) | |
IDC + DCIS | 5.6 (1) | 5.3 (1) | |
No information | – | 5.3 (1) | |
TNM classification % (n) | |||
Tumor in situ | 16.7 (3) | – | – |
I | 16.7 (3) | 5.3 (1) | 0.212 |
II | 38.9 (7) | 47.4 (9) | |
III | 27.8 (5) | 42.1 (8) | |
No information | – | 5.3 (1) | |
Estrogen receptor (ER) % (n) | |||
ER+ | 77.8 (14) | 73.7 (14) | 1.000 |
ER- | 16.7 (3) | 15.8 (3) | |
No information | 5.6 (1) | 10.8 (2) | |
Progesterone receptor (PR) % (n) | |||
PR+ | 66.7 (12) | 57.9 (11) | 1.000 |
PR- | 27.8 (5) | 31.6 (6) | |
No information | 5.6 (1) | 10.5 (2) | |
Human epidermal growth factor receptor 2 (HER2) % (n) | |||
HER2+ | 33.3 (6) | 26.3 (5) | 1.000 |
HER2- | 61.1 (11) | 63.2 (12) | |
No information | 5.6 (1) | 10.5 (2) |